The serine/threonine kinase LKB1 is a well-characterized tumor suppressor that governs diverse cellular processes, including growth, polarity, and metabolism. Somatic-inactivating mutations in LKB1 are observed in about 15% to 30% of non-small cell lung cancers (NSCLC). LKB1 inactivation confers lung adenocarcinomas (ADC) with malignant features that remain refractory to therapeutic intervention. YAP activation has been linked to LKB1 deficiency, but the role of YAP in lung ADC formation and progression is uncertain. In this study, we showed that ectopic expression of YAP in type II alveolar epithelial cells led to hyperplasia in mouse lungs.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide (1) . Non-small cell lung cancer (NSCLC), accounting for approximately 85% of all cases, is a major subgroup of lung cancer, which is often diagnosed at advanced stage and holds poor prognosis (2) . Adenocarcinoma (ADC) is one of the common histologic subtypes of NSCLC (3) . Although the pathogenesis of ADC is partially understood and new therapeutic options have substantially increased the survival of patients with ADC over the last decade, it still remains as largely incurable (4) . Thus, further mechanistic insights into lung ADC carcinogenesis are urgently needed to pave the way for the development of effective therapeutic strategies.
The serine/threonine kinase gene LKB1 (also known as STK11), which is originally characterized as a tumor suppressor responsible for Peutz-Jeghers syndrome, has been implicated in coordinating a wide range of fundamental cellular processes, including polarity, metabolism, and growth, through its downstream kinases (5) . LKB1 is somatically mutated in 15% to 30% of NSCLC, making it one of the most prevalently mutated tumor suppressors in human lung cancer (6) . Studies of human NSCLC specimens and genetically engineered mouse models (GEMM) have revealed that LKB1 inactivation confers tumors with distinct biologic features. For instance, LKB1 mutations were more frequently observed in patients with poorly differentiated ADC (7) . A lung cancer mouse model harboring simultaneous activation of Kras and biallelic deletion of Lkb1 exhibits short latency, increased tumor burden and frequent metastasis. Those Lkb1 deficiency tumors also have an expanded histologic spectrum (e.g., adenocarcinoma and squamous cell carcinoma; ref. 8) . Our recent work demonstrate that Lkb1-deficient lung ADC can progressively transdifferentiates into squamous cell carcinoma (SCC), via a pathologically mixed Ad-SCC intermediate (9) , indicating the high plasticity of this specific subset of lung cancer. Interestingly, we recently found that the ADC to SCC transdifferentiation represents a novel mechanism for the development of resistance to certain preclinical drugs, including phenformin, targeting cancer metabolism (10) . Thus, this mouse model represents a clinical-relevant NSCLC subtype, which shows malignant phenotype without effective therapeutic regimens (8) . Our previous work have revealed that targeting LOX and NEDD9 by LOX enzymatic inhibitor or Nedd9 RNAi achieved partial inhibition on Lkb1-deficient tumor progression (11, 12) . Considering the limited inhibitory efficacy on LOX and NEDD9, we propose other molecules may play pivotal roles in mediating tumor progression evoked by Lkb1 loss.
Recent work has shown that YAP, the major executor of the Hippo pathway, is activated in Lkb1-mutant tumors (13) . The Hippo pathway is an emerging kinase cascade governing organ size through balancing cell proliferation and apoptosis (14) . In mammals, the Hippo pathway is composed of upstream kinase cassette, including MST1/2, LATS1/2, and two primary downstream effectors, YAP and TAZ. When the Hippo pathway is activated, the kinases MST1 and MST2 phosphorylate and activate the LAST1/2 kinases, which in turn phosphorylate YAP and TAZ, leading to the cytoplasmic retention of downstream effectors (15) . Accumulating evidence suggests that dysregulation of the Hippo pathway plays a crucial role in cancer development (16) . The upstream components of the Hippo pathway are reported to be frequently inactivated by mutations or epigenetic silencing, whereas the downstream effectors YAP and TAZ are often hyperactivated in a wide spectrum of human cancers (17) . Further functional studies have characterized YAP as an oncogenic driver in multiple cancers, including liver and skin cancers (18, 19) . YAP is also highly expressed in human lung ADC and is associated with poor clinical outcomes (20) . Although overexpression of YAP promotes proliferation and invasion in ADC cell lines, the role of YAP in de novo lung cancer formation and progression in the context of Lkb1-deficient ADC still remains elusive.
Here, we show that lineage-specific overexpression of YAP in type II alveolar epithelial cells leads to hyperplasia in mouse lungs. We further present functional evidence that YAP is an important mediator of Lkb1-deficient ADC progression through genetic studies in mice. Mechanistic studies identified survivin as a downstream mediator of YAP in Lkb1-deficient ADC malignant progression.
Materials and Methods

Mouse cohorts and treatment
All mice were housed in a specific pathogen-free environment at the Shanghai Institute of Biochemistry and Cell Biology and treated in strict accordance with protocols approved by the Institutional Animal Care and Use Committee of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. G12D /Lkb1 L/L mice were generated as previously described (8) . To make the SP-C-YAP transgenic mice, a DNA fragment containing the YAP-coding region with the SV40 poly A was ligated to the 3.7-kb region of the human SP-C promoter (21) and was microinjected into C57 blastocysts. PCR strategy was used to screen mice bearing the SP-C-YAP fragment. Among the three lines positive for SP-C-YAP, we chose two with relatively higher YAP expression for further crossing with Kras G12D mice to generate the SP-C-YAP, Kras G12D mouse cohort. Adeno-Cre infections were carried out as previously described (9) . Briefly, SP-C-YAP, Kras G12D , and
(YKL) mice were treated with 2 Â 10 6 PFU Adeno-Cre via nasal inhalation and analyzed after 24 and 11 weeks of treatments, respectively.
Xenograft assay
Kras G12D /Lkb1 L/L ADC primary cells were established as previously described (9) . Indicated groups of cells were subcutaneously transplanted into either side of nude mice (n ¼ 5). Tumor volume was measured every other day. Mice were sacrificed 3 weeks later for tumor weight and pathologic analysis.
Histopathologic analysis
All mice were euthanized for gross inspection and histopathologic examination. Xenograft tumors and mice lungs were isolated and fixed in 4% formalin. Lung lobes were embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Histologic examinations were performed by the pathologist. Tumor number was counted under microscope, and tumor area was quantified using ImageJ software by measuring pixel units.
Immunohistochemical analyses
Immunohistochemistry was performed as described previously (22) . Paraffin-embedded lung tissues and xenograft tumors were incubated with the following antibodies: anti-Yap (Cell Signaling Technology; 1:500 dilution), anti-Ki67 (Leica; 1:500 dilution), and anti-cleaved caspase-3 (Cell Signaling Technology; 1:500 dilution), anti-survivin (Santa Cruz Biotechnology; 1:200 dilution). The proliferation rate was evaluated by counting Ki67-positive nuclear staining at high-power field for more than 30 fields for each group. The apoptosis was assessed by the analysis of cleaved caspase-3 immunostaining. The survivin immunostaining was reviewed and scored blindly into three criteria as low, medium, and high expression. Representative pictures of each grade were shown in Supplementary Fig. S4D .
MTT assay
Kras G12D /Lkb1 À/À ADC primary cells of indicated groups were seeded in a 96-well plate, and the viability of cells was assessed by the MTT assay daily for 5 days. Briefly, 20 mL of MTT working solution (5 mg/mL) was added into each well and incubated at 37 C for 4 hours. The supernatants were then removed, and the resultant MTT formazan was dissolved in 100 mL of DMSO. The absorbance was measured at the wavelengths of 570 and 630 nm.
RT-PCR and quantitative real-time PCR
Total RNA was extracted and retro-transcribed into first-strand complementary DNA as previously described (23) . cDNAs were subjected to quantitative real-time PCR with gene-specific primers on the 7500 Fast Real-Time PCR System using SYBR-Green Master PCR mix.
Sequences of real-time PCR primers are listed as follows:
Human/mouse YAP-reverse: TGAGCTCGAACATGCTGTGG-AGTCAG.
Immunoblotting
Cells were lysed in lysis buffer and subjected to Western blot analysis with the following primary antibodies: anti-Yap (Cell Signaling Technology, 1:500 dilution), anti-survivin (Cell Signaling Technology, 1:500 dilution), and anti-actin (Sigma, 1:5,000 dilution).
Plasmids
To construct the survivin expression plasmid, the coding sequence of survivin was amplified with primers: forward: GCTCTAGAGCCACCATGGGATACCCCTACGACGTCCCCGAC-TACGCCATGGGAGCTCCG GCGCTGCCCCAGA; reverse: ACGGATCCTTAGGCAGCCAG-CTGCTCAATT.
To generate the Yap and survivin knockdown construct, the following oligonucleotides were cloned into pLKO.1 at the AgeI/EcoRI sites:
shYap-1:
Statistical analyses Statistical analyses were performed by the Student t test (twotailed) using Prism GraphPad software. Differences with P < 0.05 were considered statistically significant. Data were represented as mean AE SEM.
Results
Overexpression of YAP in type II alveolar epithelial cells induces hyperplasia in mouse lungs
To understand the role of YAP in lung tumor initiation, we took advantage of a transgenic mouse model with ectopic YAP expression, specifically in type II alveolar epithelial cells. Microscopic analyses revealed that all of mice (YAP Tg#43, 8/8, and YAP Tg#31, 5/5) with constitutive YAP expression harbored hyperplasia in the lung ( Fig. 1A; Supplementary Fig. S1A ). Detailed molecular analyses showed that those hyperplasic lesions exhibited strong YAP staining and high Ki67-positive rate (Fig. 1B) , indicating that ectopic expression of YAP confers lung epithelial cells with high proliferating potential and YAP is sufficient to drive hyperplasia in the lung.
Ectopic expression of YAP promotes de novo lung cancer progression in the Kras
G12D mouse model We next asked if YAP affects lung ADC progression driven by oncogenic Kras in vivo. To address this, we crossed the SP-C-YAP transgenic mice with Kras G12D mice to obtain SP-C-YAP, Kras G12D mice. Mice were given with Adeno-Cre by nasal inhalation and sacrificed for gross inspection and pathologic studies 24 weeks after viral administration ( Fig. 2A) . Ectopic YAP expression, which was confirmed by immunostaining analyses (Fig. 2B) , did not cause a significant change in the total tumor number ( Supplementary  Fig. S2A ). As compared with the control group, SP-C-YAP, Kras G12D mice showed a dramatic increase in tumor burden as measured by tumor size ( Fig. 2C and D; Supplementary Fig. S2B ). Ectopic YAP expression increased the number of large tumors (!1 mm 2 ), indicating that YAP promotes the lung tumor progression driven by oncogenic KRAS (Fig. 2E) . Consistently, a higher proliferation rate evidenced by Ki67 staining was observed in lung tumors from SP-C-YAP, Kras G12D mice, suggesting that YAP overexpression exhibited a promotive effect on tumor cell growth (Fig. 2F) .
Homozygous deletion of Yap inhibits
, KL in short). In line with recent studies (13), ADC derived from KL mice exhibits high Yap expression and focused nuclear localization compared with those from Kras G12D mice (Supplementary Fig. S3A ). As Yap is hyperactivated in KL mice, we then crossed Yap L/L mice with
L/L (YKL) mice. KL and YKL mice were treated with Adeno-cre and analyzed 11 weeks after viral infection (Fig. 3A) . Biallelic deletion of Yap, which was validated by Yap immunostaining (Fig. 3B) , did not affect the total tumor number (Supplementary Fig. S3B ). However, the tumor size in YKL mice was significantly reduced compared with the control group (Fig. 3C and D) , and the number of large tumors (!1 mm 2 ) was significantly reduced in the YKL group (Fig. 3E) . Detailed pathologic analyses revealed that the majority of the lesions from the YKL model were atypical adenomatous hyperplasia (AAH) or adenoma, and the SCC were rarely detected ( Supplementary Fig. S3C ), indicating that Yap deletion significantly inhibited lung cancer progression in KL mice. Tumors from YKL mice displayed a moderate decrease of Ki67-positive cells and a significant increase of cleaved caspase-3-positive cells ( Fig. 3F and G) , suggesting the essential role of Yap in maintaining ADC cell survival.
Survivin acts as a downstream mediator of YAP in promoting malignant progression of LKB1-deficient lung ADC
To study the potential mechanisms involved in the promotive role of YAP in LKB1-deficient ADC malignant progression, we knocked down the Yap level in primary Kras G12D /Lkb1 À/À adenocarcinoma cells. Survivin, a member of the inhibitor of apoptosis (24) , was most significantly downregulated among the examined Yap target genes (Fig. 4A) . This was further 
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YAP Tg #31,Kras (Fig. 4B) . Consistent with these findings, lung tumors from SP-C-YAP, Kras G12D mice showed an increased survivin level in comparison with those from Kras G12D mice (Fig. 4C) , whereas lung tumors from YKL mice exhibited a marked decrease of survivin compared with those from KL mice (Fig. 4D) , providing a potential link between Yap and survivin in regulating lung tumorigenesis.
YAP Mediates Progression of
To further prove the functional link between Yap and survivin, MTT and xenograft assays were performed in mouse Kras G12D / Lkb1 À/À primary cells. Our data clearly showed that survivin knockdown significantly inhibited cell proliferation in vitro and tumor growth in vivo ( Fig. 4E-4 ; Supplementary Fig. S4B ). Similar inhibition was observed when YAP was knocked down ( Fig. 4I-K ; Supplementary Fig. S4C ). Consistently, decreased cell proliferation was observed when either survivin or YAP was knocked down (Fig. 4H and L) . Importantly, survivin overexpression rescued the inhibitory function of Yap knockdown upon cell proliferation in vitro, tumor growth, and cell proliferation in vivo ( Fig. 4I-L; Supplementary Fig. S4C ). Together, these data support the notion that survivin serves as a downstream mediator of YAP in Lkb1-deficient ADC malignant progression.
Discussion
In this study, we investigate the role of YAP in lung ADC formation and progression utilizing de novo lung cancer mouse models and demonstrate that those Lkb1-mutant ADC are addicted to YAP activation. Ectopic expression of YAP in lung type II alveolar epithelial cells results in hyperplasia. Overexpression of YAP in Kras G12D mice significantly promotes de novo lung ADC progression, whereas homozygous deletion of Yap in Kras G12D /Lkb1 L/L mice dramatically inhibits the malignant progression. YAP is a well-documented oncogene in a wide range of cancer types. Studies in mice have shown that activation of YAP leads to striking tissue overgrowth and tumor formation in multiple organs. For instance, overexpression of YAP in the liver drives liver enlargement as well as liver tumor formation (18) . Activation of YAP triggers the expansion of epidermal stem cell compartment and the formation of SCC-like tumors in mouse skin (19) . Activation of YAP is potently prometastatic in breast cancer and melanoma cells (25) . However, increasing evidence indicates the suppressive role of YAP in several cancer types or under certain conditions. For example, knockdown of YAP in breast cancer cell lines suppresses cell anoikis and enhances the cell migration and invasion ability (26) . YAP is described to interact with and enhance p73-dependent apoptosis in response to DNA damage (27) . Thus, the function of YAP in tumorigenesis may be context dependent.
A recent study from Lau and colleagues (28) has shown that activation of Yap in combination with mutant Kras results in an increase in tumor number and higher tumor grade (28) . Using SP-C-YAP transgenic mice, we have shown that YAP overexpression does not cause a significant change in the total tumor number. This could be due to different genetic modification systems as well as the potentially differential YAP expression level. Consistent with the findings of Lau and colleagues (28), we found that ectopic expression of YAP did result in a dramatic increase in tumor burden, indicative of accelerated lung tumor progression. In addition, taking advantage of the primary cell line derived from Kras/p53 lung ADC, Lau and colleagues have found that knockdown of Yap/Taz attenuates the metastasis potential of cells (28) . Instead of studying cancer metastasis, our work focuses on the role of Yap in tumor formation using the Kras G12D /Lkb1 L/L mouse model, in which the de novo lung ADC can progressively transdifferentiate into SCC. Our recent work has shown that Yap knockdown using lenti-shRNA delivery in KL mice promotes the ADC to SCC transdifferentiation (23) . In contrast, homozygous deletion of YAP in this model resulted in a dramatic inhibition of lung ADC progression. Indeed, a majority of lesions from the YKL model are AAH or adenoma with small tumor volume, and large tumors are significantly decreased. The SCC are seldom observed in the YKL model. However, this does not mean that YAP homozygous deletion inhibits the AST process because lung ADC progression, which is known to be required for AST (9) , is also significantly inhibited. Our data, together with previous reports (28) , support that YAP is important for lung ADC formation and malignant progression despite different genetic approaches.
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Notably, we identify survivin as a crucial mediator of YAP in Lkb1-deficient ADC malignant progression. Survivin (encoded by Birc5) is a member of the family of inhibitor of apoptosis proteins (IAP). It plays a prominent role in cell-cycle progression and antagonizes cell death through directly inhibiting active caspases (24) . Survivin is one of the most tumorspecific molecules because elevated expression of survivin has been observed in some cancer types (29, 30) . Survivin has been reported as a YAP target because a marked increase in the survivin level was observed upon YAP activation (31) . Here, we determined a functional link between Yap and survivin in the context of Lkb1-deficient lung ADC by utilizing a Kras G12D /Lkb1 À/À adenocarcinoma primary cell line.
Knockdown of Yap decreased the mRNA and protein level of survivin. Reexpression of survivin rescued the suppressed cell proliferation and impaired tumor growth upon Yap knockdown. Thus, our findings not only confirm the regulatory relationship between Yap and survivin, but also provide functional evidence that survivin serves as an executor of Yap in promoting malignant progression. LKB1 exerts its tumor suppressive effect via regulating cell growth, reprogramming cell metabolism, and modulating cell polarity through distinct downstream kinases (5) . Emerging evidence has linked YAP to LKB1 because YAP activation is a hallmark of LKB1-mutant tumors, and LKB1 restoration decreases YAP nuclear localization (13, 32) . Using Kras
G12D
and Kras G12D /Lkb1 L/L lung cancer mouse models with different endogenous YAP expression levels, we provided evidence that YAP is a crucial mediator of malignant progression of Lkb1-deficient lung ADC. Meanwhile, Mohseni and colleagues (13) also demonstrated that deletion of Yap in the liver suppresses hepatomegaly and hepatocyte hyperplasia induced by acute deletion of Lkb1. Therefore, our data not only clarify the functional importance of YAP in the lung cancer progression evoked by Lkb1 loss, but also corroborate the notion that the functional relationship between LKB1 and YAP is concordant among organs.
LKB1 is one of the frequently mutated tumor suppressors in human NSCLC. Loss of LKB1 contributes to more aggressive phenotype with limited therapeutic options (8, 9, 33, 34) . Recently, increasing efforts have been made to identify a powerful therapeutic strategy for Lkb1-deficient lung cancer. Combined inhibition of PI3K-mTOR, MEK, and SRC family kinases resulted in significant tumor regression in Kras G12D /Lkb1 L/L lung tumors (35) . Shackelford and colleagues (36) have identified phenformin as a cancer metabolism-based therapeutic drug to target Lkb1-deficient tumors. Based on our genetic studies in mice, we propose that targeting YAP may serve as a potential therapeutic approach for the LKB1-deficient lung tumor. Moreover, considering the prevalence of LKB1 mutations in multiple cancer types, our work may also provide significant implication for the treatment of other LKB1-deficient cancers.
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